Adial Pharmaceuticals - Proyeksi bathi mangsa ngarep ADIL

Logo perusahaan publik Adial Pharmaceuticals Inc. (ADIL)

Adial Pharmaceuticals focuses on alcoholism therapy via the AD04 drug for individuals with a genetic predisposition. The financial return forecast demonstrates market expectations, where the value of expresses the metric level. The development of personalized treatment methods relies on partnerships with psychiatric centers. The absence of direct competitors in the genetic targeting niche strengthens the issuer's position before investors.

ADIL: Proyeksi bathi mangsa ngarep Adial 04.07.2022 - 17.11.2026

Rincian analitis perusahaan Adial Pharmaceuticals

Analisis dhasar perusahaan:Adial, ADIL
Barang utama Adial Pharmaceuticals, Inc.

This indicator measures the corporation's expected net income to determine its intrinsic value. Projected financial results on GURU.Markets visualize capital dynamics through the lens of future cash flows. The metric is calculated as the difference between expected revenue and total operating expenses. Growth in this indicator confirms the fundamental stability of Adial Pharmaceuticals (ADIL). This is critical during prolonged FDA trials and the protection of unique patents for receptor antagonists.